Levostatin eficacy and safety in treatment of squamous carcinoma of head and neck

The impact of adding lovastatin to definitive chemoradiation therapy on response rate and acute treatment related toxicity in patients with squamus cell carcinoma of head and neck

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20171204037739N1

Enrollment

Registered

2018-03-18

Start date

2018-02-20

Completion date

Unknown

Last updated

2018-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Squamous cell carcinoma of base of tongue. Condition 2: Squamous cell carcinoma of tongue. Condition 3: Squamous cell carcinoma of gum. Condition 4: Squamous cell carcinoma of floor of mouth. Condition 5: Squamous carcinoma of palate. Condition 6: Squamous cell carcinoma of other and unspecified parts of mouth. Condition 7: Squamous cell carcinoma of tonsil. Condition 8: Squamous cell carcinoma of oropharynx. Condition 9: Squamous cell carcinoma of nasopharynx. Condition 10: Squamo

Interventions

Intervention 1: Intervention group: Tablet Levastatin 40mg twice a day during treatment+standard chemoradiotherapy. Intervention 2: Control group: standard chemoradiotherapy.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age more than 18years old Biopsy confirmed squamous cell carcinoma of head and neck

Exclusion criteria

Exclusion criteria: Surgical resection of head head and neck mass Use of Anti inflammatory drug or Asprine more than 3days in week Use of anti cuaglane drugs, fibrate, cyclosporine, OCP, Hypersensitivity to Levastatin Life expectancy shorter than 2years Received chemotherapy perior chemoradiotherapy Pregnancy

Design outcomes

Primary

Measure	Time frame
Response rate. Timepoint: 8 weeks after treatment. Method of measurement: CT scan for response rate.	—

Secondary

Measure	Time frame
Treatment related acute toxicity. Timepoint: Weekly during treatment. Method of measurement: Labratory test and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactPari Ghadamgahi

Ahvaz University of Medical Sciences

ghadamgahi.p@ajums.ac.ir0089 61 33337401

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026